VeraDermics, Inc
VeraDermics, Inc is listed today as Veradermics, Inc: market value, financials and filings are on its company page.
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2026 | $30 M | No. 5 | $10 to $50 million | options | SEC | |
| Oct 2025 | $135 M | No. 4 | $50 to $250 million | equity | SEC | |
| Nov 2024 | $67 M | No. 3 | $50 to $250 million | equity | SEC | |
| Apr 2023 | $15 M | No. 2 | $10 to $50 million | equity | SEC | |
| Sep 2021 | $22 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
VeraDermics, Inc chose not to state its revenue in its newest notice of a funding round (May 2026).
SEC Form D · May 2026
The industry group it chose in its notices: Other Health Care.
SEC Form D · May 2026
That is all the official record says: VeraDermics, Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of VeraDermics, Inc are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Jane M. Grant-Kels | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2026) | SEC Form 3 |
| Longitude 103.8 East, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Longitude 103.8 East Partners, LLC | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Longitude Capital Partners V, LLC | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Longitude Venture Partners V, L.P. | Venture capital | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2026) | SEC Form 3 |
| Reid Alexander Waldman | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2026) | SEC Form 3 |
| Timothy August Durso | Person | not stated | not stated | Held Series A preferred stock (Form 3, 2026) | SEC Form 3 |
| Vlad Coric | Person | not stated | not stated | Held Series C preferred stock, director (Form 3, 2026) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 41 investors.
Largest shareholders today
Institutions holding Veradermics, Inc shares, as of Sep 30, 2026.
- Montanova Capital, LLC$451 M8.81%
- FMR LLC$371 M7.26%
- Jpmorgan Chase & Co$288 M5.62%
- SR One Capital Management, LP$252 M4.93%
- Citadel Advisors LLC$248 M4.85%
- BlackRock, Inc.$234 M4.57%
- Deep Track Capital, LP$230 M4.50%
- Siren, L.L.C.$161 M3.14%
- D. E. Shaw & Co., Inc.$154 M3.00%
- Vanguard Capital Management LLC$145 M2.84%
- Adage Capital Partners GP, L.L.C.$130 M2.54%
- Aberdeen Group plc$120 M2.35%
- Maverick Capital LTD$114 M2.23%
- Infinitum Asset Management, LLC$101 M1.97%
- Jennison Associates LLC$99 M1.93%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Dominic Carrano | Executive officer | May 2026 |
| Mark Neumann | Executive officer | May 2026 |
| Michael Greco | Executive officer | May 2026 |
| Reid Waldman | Executive officer | May 2026 |
| Tim Durso | Executive officer | May 2026 |
| Reid W. Waldman | Executive officer | Dec 2024 |
| Timothy Durso | Executive officer | May 2023 |
| David Friedman | Director | May 2026 |
| Jane Grant-Kels | Director | May 2026 |
| John Childs | Director | May 2026 |
| Katarina Pance | Director | May 2026 |
| Patrick Enright | Director | May 2026 |
| Reid Waldman | Director | May 2026 |
| Vladimir Coric | Director | May 2026 |
| Amanda Birdsey-Benson | Director | Oct 2025 |
| Amanda W. Birdsey-Benson | Director | Dec 2024 |
| Christopher W. Eklund | Director | Dec 2024 |
| Jane W. Grant-Kels | Director | Dec 2024 |
| John W. Childs | Director | Dec 2024 |
| Patrick W. Enright | Director | Dec 2024 |
| Reid W. Waldman | Director | Dec 2024 |
| Vladimir W. Coric | Director | Dec 2024 |
| Timothy Durso | Director | May 2023 |
Went public since 2026. Its SEC number is that of a company listed on a stock exchange.